EntryPoint Capital’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$863K Buy
30,831
+10,950
+55% +$308K 0.21% 118
2026
Q1
$567K Buy
19,881
+12,780
+180% +$436K 0.17% 207
2025
Q4
$281K Sell
7,101
-4,422
-38% -$162K 0.11% 393
2025
Q3
$406K Sell
11,523
-2,162
-16% -$74.5K 0.16% 239
2025
Q2
$448K Sell
13,685
-11,483
-46% -$373K 0.22% 133
2025
Q1
$812K Buy
+25,168
New +$934K 0.37% 13
2024
Q4
Sell
-14,250
Closed -$400K 717
2024
Q3
$400K Sell
14,250
-1,026
-7% -$25.3K 0.23% 128
2024
Q2
$348K Buy
15,276
+4,138
+37% +$95.5K 0.16% 125
2024
Q1
$339K Buy
11,138
+3,986
+56% +$134K 0.3% 13
2023
Q4
$255K Buy
+7,152
New +$266K 0.24% 43

Other funds holding ATRC

EntryPoint Capital's ATRC Position: Q2 2026 in Review

EntryPoint Capital increased its AtriCure (ATRC) stake by 55% in Q2 2026, buying an estimated $308K and bringing the position to 30,831 shares worth $863K. The position accounts for 0.21% of the portfolio, ranked #118.

EntryPoint Capital first reported a position in ATRC in Q4 2023 and has held it in 10 quarters since. 251 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

  • EntryPoint Capital held 30,831 shares of AtriCure worth $863K as of Q2 2026.
  • EntryPoint Capital bought 10,950 AtriCure shares in Q2 2026, an estimated $308K.
  • AtriCure made up 0.21% of EntryPoint Capital's portfolio in Q2 2026, its #118 holding.
  • EntryPoint Capital first reported a position in AtriCure in Q4 2023 and has held it in 10 quarters since.
  • 251 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.